Under normal conditions, stem cells bearing TP53 mutations are no more likely to replace their neighboring wild type stem cells within the crypt base, while APC and KRAS mutations, which are more frequently encountered in sporadic CRC (75), offer a clear survival/growth advantage. This evidence concerns the gene KRAS and colorectal carcinoma.